blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability
Register Forum

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
FAQ - Register Alert
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP3840747

EP3840747 - NOVEL ARYLOXYPIPERIDINE PYRAZOLE COMPOUNDS AS INDOLEAMINE 2,3-DIOXYGENASE INHIBITORS [Right-click to bookmark this link]
StatusNo opposition filed within time limit
Status updated on  02.02.2024
Database last updated on 03.09.2024
FormerThe patent has been granted
Status updated on  24.02.2023
FormerGrant of patent is intended
Status updated on  11.10.2022
FormerRequest for examination was made
Status updated on  28.05.2021
FormerThe international publication has been made
Status updated on  28.02.2020
Most recent event   Tooltip02.08.2024Lapse of the patent in a contracting state
New state(s): BE		published on 04.09.2024 [2024/36]
Applicant(s)For all designated states
Merck Sharp & Dohme LLC
126 East Lincoln Avenue
Rahway, New Jersey 07065 / US
[2022/42]
Former [2021/26]For all designated states
Merck Sharp & Dohme Corp.
126 East Lincoln Road
Rahway, New Jersey 07065-0907 / US
Inventor(s)01 / CLAUSEN, Dane
2000 Galloping Hill Road
Kenilworth, New Jersey 07033 / US
02 / FRADERA, Xavier
33 Avenue Louis Pasteur
Boston, Massachusetts 02115-5727 / US
03 / GUO, Liangqin
2000 Galloping Hill Road
Kenilworth, New Jersey 07033 / US
04 / HAN, Yongxin
33 Avenue Louis Pasteur
Boston, Massachusetts 02115-5727 / US
05 / HE, Shuwen
158 Second Street
Fanwood, New Jersey 07023 / US
06 / HUANG, Xianhai
16 Hemlock Circle
Warren, New Jersey 07059 / US
07 / KOZLOWSKI, Joseph
1066 Stuart Road
Princeton, New Jersey 08540 / US
08 / LI, Guoqing
2000 Galloping Hill Road
Kenilworth, New Jersey 07033 / US
09 / LIM, Jongwon
33 Avenue Louis Pasteur
Boston, Massachusetts 02115-5727 / US
10 / MARTINOT, Theodore, A.
33 Avenue Louis Pasteur
Boston, Massachusetts 02115-5727 / US
11 / PASTERNAK, Alexander
33 Avenue Louis Pasteur
Boston, Massachusetts 02115-5727 / US
12 / SCIAMMETTA, Nunzio
33 Avenue Louis Pasteur
Boston, Massachusetts 02115-5727 / US
13 / VERRAS, Andreas
250 W. 27th St. Apt. 6B
New York, New York 10001 / US
14 / XIAO, Li
2000 Galloping Hill Road
Kenilworth, New Jersey 07033 / US
15 / YU, Wensheng
2000 Galloping Hill Road
Kenilworth, New Jersey 07033 / US
16 / ZHANG, Rui
2000 Galloping Hill Road
Kenilworth, New Jersey 07033 / US
 [2021/26]
Representative(s)Merck Sharp & Dohme LLC
120 Moorgate
London EC2M 6UR / GB
[2023/13]
Former [2021/26]Hussain, Deeba
Merck Sharp & Dohme Corp.
120 Moorgate
London, EC2M 6UR / GB
Application number, filing date19852632.916.08.2019
[2021/26]
WO2019US46724
Priority number, dateUS201862721283P22.08.2018         Original published format: US 201862721283 P
[2021/26]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2020041100
Date:27.02.2020
Language:EN
[2020/09]
Type: A1 Application with search report 
No.:EP3840747
Date:30.06.2021
Language:EN
The application published by WIPO in one of the EPO official languages on 27.02.2020 takes the place of the publication of the European patent application.
[2021/26]
Type: B1 Patent specification 
No.:EP3840747
Date:29.03.2023
Language:EN
[2023/13]
Search report(s)International search report - published on:US27.02.2020
(Supplementary) European search report - dispatched on:EP14.12.2021
ClassificationIPC:C07D205/04, C07D231/14, C07D401/02, A61K31/497, A61K31/415, A61K31/4155, A61P25/24, A61P25/28, A61P27/12, A61P31/12, A61P35/00, A61P37/00
[2022/02]
CPC:
A61K45/06 (EP,US); A61K31/5377 (US); A61K31/454 (US);
A61K31/4545 (US); A61K31/46 (US); A61K31/496 (US);
A61P25/24 (EP); A61P25/28 (EP); A61P27/12 (EP);
A61P31/12 (EP); A61P35/00 (EP); A61P37/00 (EP);
C07D401/06 (EP,US); C07D401/14 (EP,US); C07D413/14 (EP,US);
C07D451/06 (US) (-)
Former IPC [2021/26]A61K31/415, A61K31/4155, A61K31/497, C07D205/04, C07D231/14, C07D401/02
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2021/26]
Extension statesBANot yet paid
MENot yet paid
Validation statesKHNot yet paid
MANot yet paid
MDNot yet paid
TNNot yet paid
TitleGerman:NEUARTIGE ARYLOXYPIPERIDIN-PYRAZOL-VERBINDUNGEN ALS INDOLEAMIN-2,3-DIOXYGENASE-INHIBITOREN[2021/26]
English:NOVEL ARYLOXYPIPERIDINE PYRAZOLE COMPOUNDS AS INDOLEAMINE 2,3-DIOXYGENASE INHIBITORS[2021/26]
French:NOUVEAUX COMPOSÉS ARYLOXYPIPÉRIDINE PYRAZOLE UTILES EN TANT QU'INHIBITEURS DE L'INDOLÉAMINE 2,3-DIOXYGÉNASE[2021/26]
Entry into regional phase22.03.2021National basic fee paid 
22.03.2021Search fee paid 
22.03.2021Designation fee(s) paid 
22.03.2021Examination fee paid 
Examination procedure22.03.2021Examination requested  [2021/26]
21.07.2022Amendment by applicant (claims and/or description)
12.10.2022Communication of intention to grant the patent
15.02.2023Fee for grant paid
15.02.2023Fee for publishing/printing paid
15.02.2023Receipt of the translation of the claim(s)
Opposition(s)03.01.2024No opposition filed within time limit [2024/10]
Fees paidRenewal fee
09.08.2021Renewal fee patent year 03
09.08.2022Renewal fee patent year 04
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipAT29.03.2023
CZ29.03.2023
DK29.03.2023
EE29.03.2023
ES29.03.2023
FI29.03.2023
HR29.03.2023
IT29.03.2023
LT29.03.2023
LV29.03.2023
MC29.03.2023
NL29.03.2023
PL29.03.2023
RO29.03.2023
RS29.03.2023
SE29.03.2023
SI29.03.2023
SK29.03.2023
SM29.03.2023
NO29.06.2023
GR30.06.2023
IS29.07.2023
PT31.07.2023
IE16.08.2023
LU16.08.2023
BE31.08.2023
CH31.08.2023
[2024/36]
Former [2024/33]AT29.03.2023
CZ29.03.2023
DK29.03.2023
EE29.03.2023
ES29.03.2023
FI29.03.2023
HR29.03.2023
IT29.03.2023
LT29.03.2023
LV29.03.2023
MC29.03.2023
NL29.03.2023
PL29.03.2023
RO29.03.2023
RS29.03.2023
SE29.03.2023
SI29.03.2023
SK29.03.2023
SM29.03.2023
NO29.06.2023
GR30.06.2023
IS29.07.2023
PT31.07.2023
IE16.08.2023
LU16.08.2023
CH31.08.2023
Former [2024/26]AT29.03.2023
CZ29.03.2023
DK29.03.2023
EE29.03.2023
ES29.03.2023
FI29.03.2023
HR29.03.2023
IT29.03.2023
LT29.03.2023
LV29.03.2023
MC29.03.2023
NL29.03.2023
PL29.03.2023
RO29.03.2023
RS29.03.2023
SE29.03.2023
SI29.03.2023
SK29.03.2023
SM29.03.2023
NO29.06.2023
GR30.06.2023
IS29.07.2023
PT31.07.2023
LU16.08.2023
CH31.08.2023
Former [2024/25]AT29.03.2023
CZ29.03.2023
DK29.03.2023
EE29.03.2023
ES29.03.2023
FI29.03.2023
HR29.03.2023
LT29.03.2023
LV29.03.2023
MC29.03.2023
NL29.03.2023
PL29.03.2023
RO29.03.2023
RS29.03.2023
SE29.03.2023
SI29.03.2023
SK29.03.2023
SM29.03.2023
NO29.06.2023
GR30.06.2023
IS29.07.2023
PT31.07.2023
LU16.08.2023
CH31.08.2023
Former [2024/21]AT29.03.2023
CZ29.03.2023
DK29.03.2023
EE29.03.2023
ES29.03.2023
FI29.03.2023
HR29.03.2023
LT29.03.2023
LV29.03.2023
MC29.03.2023
NL29.03.2023
PL29.03.2023
RO29.03.2023
RS29.03.2023
SE29.03.2023
SK29.03.2023
SM29.03.2023
NO29.06.2023
GR30.06.2023
IS29.07.2023
PT31.07.2023
LU16.08.2023
Former [2024/16]AT29.03.2023
CZ29.03.2023
DK29.03.2023
EE29.03.2023
ES29.03.2023
FI29.03.2023
HR29.03.2023
LT29.03.2023
LV29.03.2023
MC29.03.2023
NL29.03.2023
PL29.03.2023
RO29.03.2023
RS29.03.2023
SE29.03.2023
SK29.03.2023
SM29.03.2023
NO29.06.2023
GR30.06.2023
IS29.07.2023
PT31.07.2023
Former [2024/10]AT29.03.2023
CZ29.03.2023
DK29.03.2023
EE29.03.2023
ES29.03.2023
FI29.03.2023
HR29.03.2023
LT29.03.2023
LV29.03.2023
NL29.03.2023
PL29.03.2023
RO29.03.2023
RS29.03.2023
SE29.03.2023
SK29.03.2023
SM29.03.2023
NO29.06.2023
GR30.06.2023
IS29.07.2023
PT31.07.2023
Former [2023/50]AT29.03.2023
EE29.03.2023
ES29.03.2023
FI29.03.2023
HR29.03.2023
LT29.03.2023
LV29.03.2023
NL29.03.2023
PL29.03.2023
RO29.03.2023
RS29.03.2023
SE29.03.2023
SK29.03.2023
SM29.03.2023
NO29.06.2023
GR30.06.2023
IS29.07.2023
PT31.07.2023
Former [2023/49]AT29.03.2023
EE29.03.2023
ES29.03.2023
FI29.03.2023
HR29.03.2023
LT29.03.2023
LV29.03.2023
NL29.03.2023
RO29.03.2023
RS29.03.2023
SE29.03.2023
SM29.03.2023
NO29.06.2023
GR30.06.2023
PT31.07.2023
Former [2023/48]AT29.03.2023
EE29.03.2023
ES29.03.2023
FI29.03.2023
HR29.03.2023
LT29.03.2023
LV29.03.2023
NL29.03.2023
RS29.03.2023
SE29.03.2023
SM29.03.2023
NO29.06.2023
GR30.06.2023
PT31.07.2023
Former [2023/46]ES29.03.2023
FI29.03.2023
HR29.03.2023
LT29.03.2023
LV29.03.2023
NL29.03.2023
RS29.03.2023
SE29.03.2023
SM29.03.2023
NO29.06.2023
GR30.06.2023
PT31.07.2023
Former [2023/38]FI29.03.2023
HR29.03.2023
LT29.03.2023
LV29.03.2023
NL29.03.2023
RS29.03.2023
SE29.03.2023
NO29.06.2023
GR30.06.2023
Former [2023/37]FI29.03.2023
HR29.03.2023
LT29.03.2023
LV29.03.2023
RS29.03.2023
SE29.03.2023
NO29.06.2023
GR30.06.2023
Former [2023/36]FI29.03.2023
HR29.03.2023
LT29.03.2023
LV29.03.2023
RS29.03.2023
SE29.03.2023
NO29.06.2023
Former [2023/35]HR29.03.2023
LT29.03.2023
RS29.03.2023
NO29.06.2023
Former [2023/34]LT29.03.2023
RS29.03.2023
Former [2023/33]LT29.03.2023
Cited inInternational search[A]US2018186787  (COWLEY PHILLIP M [GB], et al) [A] 1-3* entire document *
 [A]  - PUBCHEM, (20150223), Database accession no. 241430767 [A] 1-3 * . entire document *
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.